Acknowledging and addressing the gender disparity in pre-exposure prophylaxis use for HIV prevention
Journal of Pharmaceutical Health Services Research · 08.10.2022 · 13 (3) · 168-171
DOI: 10.1093/jphsr/rmac025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Health Services Research, online erschienen am 18.07.2022. Verfasst von Dion C Allen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sociobehavioral and Administrative Pharmacy, Nova Southeastern University College of Pharmacy, Davie, FL, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: University of Puerto Rico, National Institute of Mental Health.
Abstract (Originalsprache)
Objective
One in four persons living with HIV in the USA is a woman. While the annual HIV diagnoses for 2019 decreased by approximately 9% when compared with 2015, this decrease was seen in men, while the rates remained stable for women. Pre-exposure prophylaxis (PrEP) is one major biomedical tool that could benefit women at risk of HIV. However, women only account for approximately 5% of PrEP users annually. The objective of this study is to identify and address the gender disparity in PrEP use.
Methods
This study used epidemiological data from the AIDSVu database to confirm the presence of a gender disparity in PrEP use across the USA. Cross-sectional data from 2019 showed that PrEP use was significantly higher in men, which suggested the existence of a disparity. The PrEP-to-Need ratio was then used to examine the trends in PrEP use relative to the rate of HIV infections, from 2012 to 2019, and to confirm the existence of the gender disparity in PrEP use. Key findings There is a marked gender disparity in PrEP use. This disparity is widening and therefore demands more attention to women at risk of HIV. Some recommendations for addressing the disparity include the following: raising awareness, capacity building for providers, scaling up efforts to better reach women at risk of HIV and additional research to understand the drivers of the disparity.
Conclusions
Policy makers could therefore prioritize the health outcomes of women by promoting research and education aimed at extending PrEP offerings to effectively reach women.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sociobehavioral and Administrative Pharmacy, Nova Southeastern University College of Pharmacy, Davie, FL, USA.
- Obstetrics and Gynecology, Maternal-Infant Studies Center, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, Puerto Rico.
ORCID-Profile: Dion C Allen
Förderung
- University of Puerto Rico
- National Institute of Mental Health
Zitieren
APA
Allen, D. C., Rabionet, S. E., Popovici, I., & Zorrilla, C. D. (2022). Acknowledging and addressing the gender disparity in pre-exposure prophylaxis use for HIV prevention. Journal of Pharmaceutical Health Services Research, 13(3), 168-171. https://doi.org/10.1093/jphsr/rmac025
Vancouver
Allen DC, Rabionet SE, Popovici I, Zorrilla CD. Acknowledging and addressing the gender disparity in pre-exposure prophylaxis use for HIV prevention. Journal of Pharmaceutical Health Services Research. 2022;13(3):168-171. doi:10.1093/jphsr/rmac025
BibTeX
@article{Allen2022,
author = {Allen, Dion C and Rabionet, Silvia E and Popovici, Ioana and Zorrilla, Carmen D},
title = {Acknowledging and addressing the gender disparity in pre-exposure prophylaxis use for HIV prevention},
journal = {Journal of Pharmaceutical Health Services Research},
year = {2022},
volume = {13},
number = {3},
pages = {168--171},
doi = {10.1093/jphsr/rmac025}
}
EUVIMED